Log in
招商证券-仙琚制药(002332)四大治疗领域专科化发展，前期布局落地迎转折之年-230510
English body is not available for this report yet; showing the Chinese version. View in Chinese
常见问题
- 这份报告主要研究什么？
- 《招商证券-仙琚制药(002332)四大治疗领域专科化发展，前期布局落地…》主要讨论：四大治疗领域专科化发展，前期布局落地迎转折之年 公司愿景是成为全世界前十名的甾体药物供应商，随着存量大品种集采完毕、新品推出，及销售、生产体系不断优化，有望迎来“开局之年”和“转折之年”。 □甾体药…
- 报告来自哪个机构？何时发布？
- 来源机构：招商证券，篇幅约 30 页。
Copyright notice
This report is aggregated from publicly available internet sources. Copyright belongs to the original authors or rights holders. If you are a rights holder and believe content on this platform infringes your rights, please email copyright@ruishubaogao.com . We will remove the content promptly after verification.